GlobeNewswire by notified

Volta Finance Limited - Net Asset Value as at 31 May 2022

Share

Volta Finance Limited (VTA / VTAS)May2022 monthly report

NOT FOR RELEASE, DISTRIBUTION, OR PUBLICATION, IN WHOLE OR PART, IN OR INTO THE UNITED STATES

*****
Guernsey, 14June2022

AXA IM has published the Volta Finance Limited (the “Company” or “Volta Finance” or “Volta”) monthly report for May. The full report is attached to this release and will be available on Volta’s website shortly (www.voltafinance.com).

PERFORMANCE and PORTFOLIO ACTIVITY

In May, the CLO market experienced a brutal price adjustment, reversing 4 months of solid outperformance relative to classic credit and equity markets. In May Volta NAV was down 11.8%, and with a year-to-date performance for Volta at -10.5%, the five-month performance has moved to be roughly in line with that of US or European High Yield, which are down respectively at -7.8% and -8.7%.

Over the investment cycle, Volta is targeting a far higher return than conventional high-yield bonds and continues to receive a cash-on-cash return in the high teens from its investments, which is our expectation even in mildly stressed markets.

In May, Volta received the equivalent of €1.6m in terms of interest and coupons. For the 6 months ended May 2022, Volta received €22.7m interest and coupons representing a 19.3% annualized cash flow to NAV.

Turning to the broad underlying asset classes, the monthly performances** were: +2.4% for Bank Balance Sheet transactions, -13.6% for CLO equity tranches; -9.0% for CLO debt; -0.4% for Cash Corporate Credit and ABS (together representing 2.9% of NAV).

At the time of writing this comment, there is anecdotal evidence of improving prices in the secondary market and we expect that part of the downward price adjustment in May to be recouped in June.

Our medium-term view is unchanged: we still think that we may see an increase in default rates: towards circa 1% this year, rising to the 2% to 3% range for 2023 (albeit US loans being less impacted than European). We consider such default levels should not be a concern given that the longer-term historical average is slightly below 3%.

Although the consensus view is that inflation is an issue, it is worthwile reflecting that inflation has not been a major problem for the credit market historically. Despite rising inflationary pressures over the last 18 months, default rates have remained very low (over the last 12 months default rates are at 0.2% in the US and 0.8% in Europe). Furthermore, the longest period of inflation (for the last 50 years) was between 1972 and 1981 and that period coincides with the longest period of benign defaults in the US (through these 10 years the US high-yield bond and loan markets averaged annual default rates close to 1.5/2%). It is all too easy to underestimate the effect of inflation on debt erosion. In 2021, the vast majority of CLO loans, both in Europe and the US were refinanced, and now have maturities in 2028/29. Everything else being equal, with 5% inflation and 2% growth, the real value of 1$ debt is only 62 cents after 7 years, far easier to refinance.

It is also worthwhile reflecting that in 2020/21, in just 2 years, corporate profits rose by 30% or so (in the US and Europe). US corporate profits (excluding financials), for example, reached an unprecedented high last year at 8% of US GDP (a 50-year record high), compared with an average level for the last 25 years of 6.18%. When considering the last 15 years (including the GFC and the Covid Crisis) defaults have tended to start to seriously materialize once corporate profits fall below 6% of GDP (the previous two lows were 4.43% in Q2 2009 and 5.49% in Q2 2020). This suggests that if overall profits were to be flat or even to decrease by 10 or 15% in the coming 2 years it is not expected to cause any significant wave of defaults.

Looking ahead to the next few quarters, we do not believe that there are any signs that Volta is likely to suffer from a diversion of cash flows from its CLO Equity positions. Indeed, Volta cashflows have been increasing every month for the last 4 months (measured as the rolling 6-month cashflows to avoid seasonality). Receiving a continuing high level of cash flows should allow us to take advantage of opportunities arising from the current market environment while maintaining the payment of a steady quarterly dividend.

As at the end of May 2022, Volta’s NAV was €233.0m or €6.37 per share.

*It should be noted that approximately 4.0% of Volta’s GAV comprises investments for which the relevant NAVs as at the month-end date are normally available only after Volta’s NAV has already been published. Volta’s policy is to publish its NAV on as timely a basis as possible to provide shareholders with Volta’s appropriately up-to-date NAV information. Consequently, such investments are valued using the most recently available NAV for each fund or quoted price for such subordinated notes. The most recently available fund NAV or quoted price was 3.4% as at30April 2022 and0.6% as at 31March 2022.

** “performances of asset classesare calculated as the Dietz-performance of the assets in each bucket, taking into account the Mark-to-Market of the assets at period ends, payments received from the assets over the period, and ignoring changes in cross-currency rates. Nevertheless, some residual currency effects could impact the aggregate value of the portfolio when aggregating each bucket.

CONTACTS

For the Investment Manager
AXA Investment Managers Paris
Serge Demay
serge.demay@axa-im.com
+33 (0) 1 44 45 84 47

Company Secretary and Administrator
BNP Paribas Securities Services S.C.A, Guernsey Branch
guernsey.bp2s.volta.cosec@bnpparibas.com
+44 (0) 1481 750 853

Corporate Broker
Cenkos Securities plc
Andrew Worne
Daniel Balabanoff
+44 (0) 20 7397 8900

*****
ABOUT VOLTA FINANCE LIMITED

Volta Finance Limited is incorporated in Guernsey under The Companies (Guernsey) Law, 2008 (as amended) and listed on Euronext Amsterdam and the London Stock Exchange's Main Market for listed securities. Volta’s home member state for the purposes of the EU Transparency Directive is the Netherlands. As such, Volta is subject to regulation and supervision by the AFM, being the regulator for financial markets in the Netherlands.

Volta’s investment objectives are to preserve capital across the credit cycle and to provide a stable stream of income to its shareholders through dividends. Volta seeks to attain its investment objectives predominantly through diversified investments in structured finance assets. The assets that the Company may invest in either directly or indirectly include, but are not limited to: corporate credits; sovereign and quasi-sovereign debt; residential mortgage loans; and, automobile loans. The Company’s approach to investment is through vehicles and arrangements that essentially provide leveraged exposure to portfolios of such underlying assets. The Company has appointed AXA Investment Managers Paris an investment management company with a division specialised in structured credit, for the investment management of all its assets.

*****

ABOUT AXA INVESTMENT MANAGERS
AXA Investment Managers (AXA IM) is a multi-expert asset management company within the AXA Group, a global leader in financial protection and wealth management. AXA IM is one of the largest European-based asset managers with 2,460 professionals and €887 billion in assets under management as of the end of December 2021.

*****

This press release is published by AXA Investment Managers Paris (“AXA IM”), in its capacity as alternative investment fund manager (within the meaning of Directive 2011/61/EU, the “AIFM Directive”) of Volta Finance Limited (the "Volta Finance") whose portfolio is managed by AXA IM.

This press release is for information only and does not constitute an invitation or inducement to acquire shares in Volta Finance. Its circulation may be prohibited in certain jurisdictions and no recipient may circulate copies of this document in breach of such limitations or restrictions. This document is not an offer for sale of the securities referred to herein in the United States or to persons who are “U.S. persons” for purposes of Regulation S under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or otherwise in circumstances where such offer would be restricted by applicable law. Such securities may not be sold in the United States absent registration or an exemption from registration from the Securities Act. Volta Finance does not intend to register any portion of the offer of such securities in the United States or to conduct a public offering of such securities in the United States.

*****

This communication is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). The securities referred to herein are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. Past performance cannot be relied on as a guide to future performance.

*****
This press release contains statements that are, or may deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "anticipated", "expects", "intends", "is/are expected", "may", "will" or "should". They include the statements regarding the level of the dividend, the current market context and its impact on the long-term return of Volta Finance's investments. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Volta Finance's actual results, portfolio composition and performance may differ materially from the impression created by the forward-looking statements. AXA IM does not undertake any obligation to publicly update or revise forward-looking statements.

Any target information is based on certain assumptions as to future events which may not prove to be realised. Due to the uncertainty surrounding these future events, the targets are not intended to be and should not be regarded as profits or earnings or any other type of forecasts. There can be no assurance that any of these targets will be achieved. In addition, no assurance can be given that the investment objective will be achieved.

The figures provided that relate to past months or years and past performance cannot be relied on as a guide to future performance or construed as a reliable indicator as to future performance. Throughout this review, the citation of specific trades or strategies is intended to illustrate some of the investment methodologies and philosophies of Volta Finance, as implemented by AXA IM. The historical success or AXA IM’s belief in the future success, of any of these trades or strategies is not indicative of, and has no bearing on, future results.

The valuation of financial assets can vary significantly from the prices that the AXA IM could obtain if it sought to liquidate the positions on behalf of the Volta Finance due to market conditions and general economic environment. Such valuations do not constitute a fairness or similar opinion and should not be regarded as such.

Editor: AXA INVESTMENT MANAGERS PARIS, a company incorporated under the laws of France, having its registered office located at Tour Majunga, 6, Place de la Pyramide - 92800 Puteaux. AXA IMP is authorized by the Autorité des Marchés Financiers under registration number GP92008 as an alternative investment fund manager within the meaning of the AIFM Directive.

*****

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Basilea reports progress on the implementation of its strategy to focus on anti-infectives27.6.2022 07:15:00 CEST | Press release

ERADICATE phase 3 study exploring ceftobiprole for the treatment of patients with Staphylococcus aureus bacteremia (SAB) expected to report results shortlySeparate transactions for TTK/PLK1 inhibitor (BAL0891) and preclinical oncology projects expected to be concluded in H2 2022 No expansion of ongoing lisavanbulin clinical studies; exploring partnering opportunitiesDerazantinib rights to be transferred back to Merck & Co. by the end of 2022No material expenses related to oncology activities beyond 2022 and sustainable profitability expected in 2023Strategy implementation on track Ad hoc announcement pursuant to Art. 53 LR Basel/Allschwil, Switzerland, June 27, 2022 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company, announced today an update on the progress made in the implementation of its strategic focus on anti-infectives. David Veitch, Chief Executive Officer, stated: “We have made significant progress in the implementation of our new strategy. Wit

Report – ERYTECH’s Combined Shareholders’ Meeting On June 24, 202224.6.2022 22:05:00 CEST | Press release

REPORT –ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 24, 2022 Cambridge, MA (U.S.) and Lyon (France), June24, 2022 – ERYTECH Pharma (Nasdaq& Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announcedthat its Annual General Meeting was held on Friday, June 24, 2022. At the meeting, all resolutions for which the Board of Directors recommended a vote in favor were adopted, including: Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2021;Allocation of the financial year's results;Approval of the statutory auditors’ special report on regulated agreements and commitments with related parties;Approval of the elements of total compensation and benefits paid or allocated for the year ended December 31, 2021, to Gil BEYEN, Chief Executive Officer and Jean-Paul KRESS, Chairman of the Board;Approval of the compens

Cleantech Building Materials: Results of Annual General Meeting24.6.2022 14:54:27 CEST | Press release

24 June 2022 CLEANTECH BUILDING MATERIALS PLC, NASDAQ FIRST NORTH GROWTH MARKET, COPENHAGEN TICKER: CBM ISIN: GBOOBD1LVD21 CLEANTECH BUILDING MATERIALS PLC Results of Annual General Meeting The Annual General Meeting (“AGM”) of Cleantech Building Materials plc (“CBM” or the “Company”) was held in London earlier today, 24 June 2022. Details of the resolutions to be considered at the AGM were published in the Notice of AGM which was posted to Shareholders on 1 June 2022 and is available on the Company’s website: www.cbm-plc.com. All resolutions as set out in the Notice of AGM were duly passed without discussion. In particular, the following resolutions were passed at the AGM. The AGM resolved to authorise the directors of the Company to allot shares and grant rights to subscribe for, or convert any security, into shares. The directors of the Company sought authority for the purposes of section 551 of the Companies Act to exercise all the powers of the Company to allot shares and grant ri

Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia24.6.2022 13:13:19 CEST | Press release

With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at least two prior tyrosine kinase inhibitor treatments1 Positive opinion based on data from pivotal Phase III ASCEMBL trial, showing a near doubling in major molecular response rate for patients treated with Scemblix® (asciminib) vs. Bosulif®* (bosutinib) (25.5% vs. 13.2%) and more than three times lower discontinuation rate due to adverse reactions (5.8% vs 21.1%) at 24 weeks1 CHMP recommendation comes after the approval of Scemblix by the US FDA and other countries’ regulatory authorities, potentially broadening access for more patients to Novartis transformative therapies in CML Basel, June 24, 2022 — Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing au

Clariant’s shareholders approve all agenda items24.6.2022 11:30:00 CEST | Press release

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Integrated Report and Group Consolidated Financial Statements for fiscal year 2021 approvedGünter von Au reelected as Chairman of the Board of DirectorsThree new candidates join the Board of Directors: Ahmed Mohamed Alumar, Roberto César Gualdoni, Naveena ShastriConfirmed distribution of CHF 0.40 per shareKPMG confirmed as statutory auditor from 2022 MUTTENZ, JUNE 24, 2022 Clariant, a focused, sustainable, and innovative specialty chemical company, today held its 27th Annual General Meeting (AGM) where the shareholders approved all agenda items and resolutions as proposed by the Board of Directors. The AGM was held virtually, where shareholders were able to exercise their rights exclusively via the independent proxy. Overall, 698'945'298 shares or around 70.19 % of the share capital of Clariant were represented. Günter von Au was reelected as Chairman of the Board of Directors. Additionally, three new members were voted to join by a large majo